Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dermal safety study of JTE-052 0.5% in healthy adult males
jRCT2031230570Phase 1Completed
- Sponsor
- Japan Tobacco
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of delgocitinib in atopic dermatitis (AD), sponsored by Japan Tobacco. Primary endpoint: Potential for skin irritation. Started Feb 2024; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230570.